A new biomarker panel in bronchoalveolar lavage for an improved lung cancer diagnosis

Journal of Thoracic Oncology

Volumn 9, Issue 10, 2014, Pages 1504-1512

  Uribarri, María ^a   Hormaeche, Itsaso ^a   Zalacain, Rafael ^b   Lopez Vivanco, Guillermo ^b   Martinez, Antonio ^a   Nagore, Daniel ^a   Begona Ruiz Arguello M ^a  

^a Proteomika SLU ^*  (Spain)

^b HOSPITAL DE CRUCES   (Spain)

Author keywords

Biomarker; Bronchoalveolar lavage; Immunoassay; Lung cancer; Proteomics

Indexed keywords

APOA1 PROTEIN; BIOLOGICAL MARKER; C REACTIVE PROTEIN; CO4A PROTEIN; GLUTATHIONE TRANSFERASE P1; HPT PROTEIN; PEROXIREDOXIN 2; PROTEIN; PUR6 PROTEIN; SAMP PROTEIN; STMN1 PROTEIN; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ARTICLE; CANCER DIAGNOSIS; CANCER GROWTH; CANCER STAGING; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOASSAY; LUNG CANCER; LUNG LAVAGE; MAJOR CLINICAL STUDY; MALE; MASS SPECTROMETRY; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SMOKING HABIT; TWO DIMENSIONAL GEL ELECTROPHORESIS; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; LUNG NEOPLASMS; METABOLISM; MIDDLE AGED; PATHOLOGY; PROCEDURES;

BRONCHOALVEOLAR LAVAGE; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SMALL CELL; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSPECTIVE STUDIES; TUMOR MARKERS, BIOLOGICAL;

EID: 84925883150     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000282     Document Type: Article

References (41)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013;63:11-30.
2. Indovina P, Marcelli E, Maranta P, et al. Lung cancer proteomics: recent advances in biomarker discovery. Int J Proteomics 2011;2011:726869.
3. Giaccone G. Clinical impact of novel treatment strategies. Oncogene 2002;21:6970-6981.
4. Pastor MD, Nogal A, Molina-Pinelo S, et al. Proteomic biomarkers in lung cancer. Clin Transl Oncol 2013;15:671-682.
5. Pio R, Garcia J, Corrales L, et al. Complement factor H is elevated in bronchoalveolar lavage fluid and sputum from patients with lung cancer. Cancer Epidemiol Biomarkers Prev 2010;19:2665-2672.
6. Schreiber G, McCrory DC. Performance characteristics of different modalities for diagnosis of suspected lung cancer: summary of published evidence. Chest 2003;123(1 Suppl):115S-128S.
7. Spira A, Beane JE, Shah V, et al. Airway epithelial gene expression in the diagnostic evaluation of smokers with suspect lung cancer. Nat Med 2007;13:361-366.
8. Oumeraci T, Schmidt B, Wolf T, et al. Bronchoalveolar lavage fluid of lung cancer patients: mapping the uncharted waters using proteomics technology. Lung Cancer 2011;72:136-138.
9. Ocak S, Sos ML, Thomas RK, et al. High-throughput molecular analysis in lung cancer: insights into biology and potential clinical applications. Eur Respir J 2009;34:489-506.
10. Sung HJ, Cho JY. Biomarkers for the lung cancer diagnosis and their advances in proteomics. BMB Rep 2008;41:615-625.
11. Magi B, Bargagli E, Bini L, et al. Proteome analysis of bronchoalveolar lavage in lung diseases. Proteomics 2006;6:6354-6369.
12. Pastor MD, Nogal A, Molina-Pinelo S, et al. Identification of proteomic signatures associated with lung cancer and COPD. J Proteomics 2013;89:227-237.
13. Ametzazurra A, Matorras R, García-Velasco JA, et al. Endometrial fluid is a specific and non-invasive biological sample for protein biomarker identification in endometriosis. Hum Reprod 2009;24:954-965.
14. Quintana L, Monasterio A, Escuredo K, et al. Identification of chitotriosidase isoforms in plasma of Gaucher disease patients by two dimensional gel electrophoresis. Biochim Biophys Acta 2006;1764:1292-1298.
15. Watari A, Takaki K, Higashiyama S, et al. Suppression of tumorigenicity, but not anchorage independence, of human cancer cells by new candidate tumor suppressor gene CapG. Oncogene 2006;25:7373-7380.
16. Niu H, Li H, Xu C, He P. Expression profile of RhoGDI2 in lung cancers and role of RhoGDI2 in lung cancer metastasis. Oncol Rep 2010;24:465-471.
17. Xu Y, Cao LQ, Jin LY, et al. Quantitative proteomic study of human lung squamous carcinoma and normal bronchial epithelial acquired by laser capture microdissection. J Biomed Biotechnol 2012;2012:510418.
18. Bortner JD Jr, Das A, Umstead TM, et al. Down-regulation of 14-3-3 isoforms and annexin A5 proteins in lung adenocarcinoma induced by the tobacco-specific nitrosamine NNK in the A/J mouse revealed by proteomic analysis. J Proteome Res 2009;8:4050-4061.
19. Yang R, Yang L, Qiu F, et al. Functional genetic polymorphisms in PP2A subunit genes confer increased risks of lung cancer in southern and eastern Chinese. PLoS One 2013;8:e77285.
20. Boult JK, Walker-Samuel S, Jamin Y, et al. Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas. J Pathol 2011;225:344-352.
21. Grigoletto A, Lestienne P, Rosenbaum J. The multifaceted proteins Reptin and Pontin as major players in cancer. Biochim Biophys Acta 2011;1815:147-157.
22. Perl A, Hanczko R, Telarico T, et al. Oxidative stress, inflammation and carcinogenesis are controlled through the pentose phosphate pathway by transaldolase. Trends Mol Med 2011;17:395-403.
23. Castleman VH, Romio L, Chodhari R, et al. Mutations in radial spoke head protein genes RSPH9 and RSPH4A cause primary ciliary dyskinesia with central-microtubular-pair abnormalities. Am J Hum Genet 2009;84:197-209.
24. Lee HJ, Kim YT, Park PJ, et al. A novel detection method of non-small cell lung cancer using multiplexed bead-based serum biomarker profiling. J Thorac Cardiovasc Surg 2012;143:421-427.
25. Oner F, Savaş I, Numanoʇlu N. Immunoglobulins and complement components in patients with lung cancer. Tuberk Toraks 2004;52:19-23.
26. Chatterji B, Borlak J. A 2-DE MALDI-TOF study to identify disease regulated serum proteins in lung cancer of c-myc transgenic mice. Proteomics 2009;9:1044-1056.
27. Bijl M, Bootsma H, Van Der Geld Y, et al. Serum amyloid P component levels are not decreased in patients with systemic lupus erythematosus and do not rise during an acute phase reaction. Ann Rheum Dis 2004;63:831-835.
28. Hamm A, Veeck J, Bektas N, et al. Frequent expression loss of Inter-alpha-trypsin inhibitor heavy chain (ITIH) genes in multiple human solid tumors: a systematic expression analysis. BMC Cancer 2008;8:25.
29. Rho JH, Roehrl MH, Wang JY. Glycoproteomic analysis of human lung adenocarcinomas using glycoarrays and tandem mass spectrometry: differential expression and glycosylation patterns of vimentin and fetuin A isoforms. Protein J 2009;28:148-160.
30. Eißmann M, Schwamb B, Melzer IM, et al. A functional yeast survival screen of tumor-derived cDNA libraries designed to identify anti-apoptotic mammalian oncogenes. PLoS One 2013;8:e64873.
31. Hayes JD, Pulford DJ. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance. Crit Rev Biochem Mol Biol 1995;30:445-600.
32. Sekine I, Minna JD, Nishio K, et al. A literature review of molecular markers predictive of clinical response to cytotoxic chemotherapy in patients with lung cancer. J Thorac Oncol 2006;1:31-37.
33. Vlachogeorgos GS, Manali ED, Blana E, et al. Placental isoform glutathione S-transferase and P-glycoprotein expression in advanced nonsmall cell lung cancer: association with response to treatment and survival. Cancer 2008;114:519-526.
34. Sun N, Sun X, Chen B, et al. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer. Cancer Chemother Pharmacol 2010;65:437-446.
35. Gao P, Yang X, Xue YW, et al. Promoter methylation of glutathione S-transferase pi1 and multidrug resistance gene 1 in bronchioloalveolar carcinoma and its correlation with DNA methyltransferase 1 expression. Cancer 2009;115:3222-3232.
36. Zeng GQ, Zhang PF, Deng X, et al. Identification of candidate biomarkers for early detection of human lung squamous cell cancer by quantitative proteomics. Mol Cell Proteomics 2012;11:M111.013946.
37. Ocak S, Friedman DB, Chen H, et al. Discovery of new membrane-associated proteins overexpressed in small-cell lung cancer. J Thorac Oncol 2014;9:324-336.
38. Chen G, Wang H, Gharib TG, et al. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics 2003;2:107-116.
39. Rana S, Maples PB, Senzer N, et al. Stathmin 1: a novel therapeutic target for anticancer activity. Expert Rev Anticancer Ther 2008;8:1461-1470.
40. Arenberg D. PET scans for lung nodules: costs and cost-effectiveness. Chest 2010;137:4-6.
41. Bigbee WL, Gopalakrishnan V, Weissfeld JL, et al. A multiplexed serum biomarker immunoassay panel discriminates clinical lung cancer patients from high-risk individuals found to be cancer-free by CT screening. J Thorac Oncol 2012;7:698-708.